MX2024011674A - Agonistas del receptor a1a-adrenérgico y métodos de uso. - Google Patents
Agonistas del receptor a1a-adrenérgico y métodos de uso.Info
- Publication number
- MX2024011674A MX2024011674A MX2024011674A MX2024011674A MX2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A
- Authority
- MX
- Mexico
- Prior art keywords
- adrenergic receptor
- methods
- alpha
- receptor agonists
- prodrug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323421P | 2022-03-24 | 2022-03-24 | |
| PCT/US2023/015914 WO2023183394A1 (en) | 2022-03-24 | 2023-03-22 | Alpha 1a-adrenergic receptor agonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011674A true MX2024011674A (es) | 2024-09-27 |
Family
ID=88101941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011674A MX2024011674A (es) | 2022-03-24 | 2023-03-22 | Agonistas del receptor a1a-adrenérgico y métodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250188060A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4499070A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025512777A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240165433A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119013020A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023240170A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245920A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315798A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011674A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023183394A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2337909C2 (ru) * | 2002-02-01 | 2008-11-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора |
| CA2637312A1 (en) * | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| DK3421471T3 (da) * | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
-
2023
- 2023-03-22 CN CN202380029402.1A patent/CN119013020A/zh active Pending
- 2023-03-22 JP JP2024556112A patent/JP2025512777A/ja active Pending
- 2023-03-22 KR KR1020247035218A patent/KR20240165433A/ko active Pending
- 2023-03-22 EP EP23775602.8A patent/EP4499070A1/en active Pending
- 2023-03-22 CA CA3245920A patent/CA3245920A1/en active Pending
- 2023-03-22 US US18/847,147 patent/US20250188060A1/en active Pending
- 2023-03-22 MX MX2024011674A patent/MX2024011674A/es unknown
- 2023-03-22 AU AU2023240170A patent/AU2023240170A1/en active Pending
- 2023-03-22 IL IL315798A patent/IL315798A/en unknown
- 2023-03-22 WO PCT/US2023/015914 patent/WO2023183394A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20250188060A1 (en) | 2025-06-12 |
| AU2023240170A1 (en) | 2024-10-31 |
| EP4499070A1 (en) | 2025-02-05 |
| CA3245920A1 (en) | 2023-09-28 |
| JP2025512777A (ja) | 2025-04-22 |
| WO2023183394A1 (en) | 2023-09-28 |
| IL315798A (en) | 2024-11-01 |
| KR20240165433A (ko) | 2024-11-22 |
| CN119013020A (zh) | 2024-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220354A (es) | Inhibidores de egfr | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| PH12022552056A1 (en) | Heterocyclic glp-1 agonists | |
| MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
| MX2022012306A (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| PH12021552805A1 (en) | Cdk inhibitors | |
| CL2023000516A1 (es) | Compuestos como agonistas de glp-1r | |
| MX2025011447A (es) | Inhibidores de kras | |
| MX2021001690A (es) | Indoles sustituidos y metodos de uso de los mismos. | |
| CR20230517A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| MX2024000230A (es) | Inhibidores de cdk2. | |
| WO2021079196A3 (en) | Mettl3 modulators | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| ECSP22092977A (es) | Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita | |
| MX2023001671A (es) | Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2024003475A (es) | Polimorfos como inhibidores de erbb. | |
| MX2021006411A (es) | Metodos para el tratamiento del cancer resistente a inhibidores de cinasa 4 y cinasa 6 dependiente de ciclina (cdk4/6). | |
| MX2023000382A (es) | Inmunomoduladores heterocíclicos. | |
| MX2025000403A (es) | Compuestos como inhibidores de myt1 | |
| WO2020236690A9 (en) | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| CO2024002909A2 (es) | Derivado de triazol sustituido, método de preparación del mismo, composición farmacéutica del mismo y uso del mismo | |
| MX2024013950A (es) | Derivado de hidroxiamida y uso del mismo | |
| MX2024011674A (es) | Agonistas del receptor a1a-adrenérgico y métodos de uso. |